Amy Visit 2: A 16-Year-Old Girl With Depression and Hypersomnia

Title:

Amy Visit 2: A 16-Year-Old Girl With Depression and Hypersomnia

Topic: Psychiatry
Relevant Terms: Adolescent, Major Depressive Disorder, Mood Disorders
Primary Audience: Family Physicians, Pediatricians, Psychiatrists
Launch Date: 26-May-11
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Curriculum Name: Diagnosis and Treatment of Adolescent Depression

Learning Objectives

Upon completion of the activity, participants should be able to:

  1. Employ evidence-based strategies in the selection and use of antidepressants when treating depression in special populations
  2. Implement individualized treatment plans for patients with depression that maximize outcomes

    Faculty

    Ronnie G. Swift, MD
    Professor and Associate Chairman, Department of Psychiatry and Behavioral Sciences,
    New York Medical College, Valhalla

    Professor of Clinical Public Health, School of Public Health, New York; New York Medical College, Valhalla
    Chief of Psychiatry and Associate Medical Director, Metropolitan Hospital Center, New York City
    Thomas Schwartz, MD
    Associate Professor, Department of Psychiatry,
    SUNY Upstate Medical University, Syracuse, NY
    Stephen M. Stahl, MD, PhD
    Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine
    Honorary Visiting Senior Fellow, University of Cambridge, UK
    Adam M. Brenner, MD
    Advisor/Content Peer Reviewer
    Associate Professor
    Director of Residency Training in Psychiatry
    Director of Medical Student Education in Psychiatry
    The University of Texas Southwestern Medical Center, Dallas, TX
    TARGET AUDIENCE
    This activity has been developed for clinicians specializing in psychiatry. There are no prerequisites. All health care providers interested in psychopharmacology, especially primary care physicians, nurses, psychologists, and pharmacists, are welcome for advanced study.

    DISCLAIMER
    Information and opinion offered by the speakers represent their viewpoints. Conclusions drawn by the audience should be derived from careful consideration of all available scientific information. Because this course is meant to educate physicians with what is currently in use and what may be available in the future, there may be "off-label" use discussed in the presentations. Speakers have been requested to inform the audience when off-label use is being discussed.

    DISCLOSURE POLICY STATEMENT
    It is the policy of The University of Texas Southwestern Medical Center Office of Continuing Medical Education to ensure balance, independence, objectivity, and scientific rigor in all directly sponsored and jointly sponsored educational activities. All participants in certified CME activities should be made aware of any affiliation or financial interest that may affect the speaker's presentation(s). Each speaker has completed and signed a conflict of interest disclosure form. The faculty members' relationships are outlined below.

    Stephen M. Stahl, MD, PhD
    Grant/Research: AstraZeneca, BioMarin, Dainippon Sumitomo, Forest, GenOmind, Lilly, Merck, Novartis, Pamlab, Pfizer, PGxHealth/Clinical Data, Schering-Plough, Sepracor, Servier, Shire, and Torrent.
    Consultant/Advisor: Advent, Alkermes, Allergan, Arena, AstraZeneca, BioMarin, Boehringer Ingelheim, Bristol-Myers Squibb, Cypress Bioscience, Dainippon Sumitomo, Eisai, Forest, GenOmind, Janssen Division of Ortho-McNeil-Janssen, Jazz, Labopharm, Lilly, Lundbeck, Meiji, Merck, Neuronetics, Novartis, Orexigen, Otsuka America, Pamlab, Pfizer, PGxHealth/Clinical Data, Rexahn, Royalty, Schering-Plough, Servier, Shire, and VIVUS.
    Speakers Bureau: Dainippon Sumitomo, Lilly, Merck, Pamlab, Sepracor, and Sunovion.
    Thomas Schwartz, MD
    Grant/Research: Cephalon, Inc.; Cyberonics; Forest Laboratories, Inc.; Forest Pharmaceuticals, Inc.
    Consultant/Advisor: Pamlab, L.L.C.
    Speakers Bureau: AstraZeneca Pharmaceuticals LP (divested); Pfizer Inc (divested); Wyeth Pharmaceuticals (divested)
    Ronnie G. Swift, MD
    Nothing to disclose.
    Adam M. Brenner, MD
    Nothing to disclose.
    Planning Committee Members
    Richard Vanderpool, CCMEP
    Sr. Continuing Education Coordinator
    University of Texas Southwestern Medical Center
    Nothing to disclose.
    Rory Daly, MPH
    Associate Director, Program Development
    Neuroscience Education Institute
    Nothing to disclose.
    Steve Smith
    President and COO
    Neuroscience Education Institute
    Nothing to disclose.
    CREDIT DESIGNATION
    The University of Texas Southwestern Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
    ACCREDITATION STATEMENT
    The University of Texas Southwestern Medical Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
    HOW TO RECEIVE CREDIT
    By reviewing the course content and successfully completing the posttest and evaluation, physicians are entitled to receive 0.5 AMA PRA Category 1 Credit™. Statements of credit will be available to print from your user history page.
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the posttest and activity evaluation.
    • Physicians who successfully complete the posttest and evaluation will receive CME credit. You must score 70% or higher on the posttest to receive credit for this activity.
    • All other participants who successfully complete the posttest and evaluation will receive a certificate of participation.
    COURSE VIEWING REQUIREMENTS
    PC
    Internet Explorer (v6 or greater) or Firefox
    MAC
    Safari
    Release Date: May 25, 2011
    Expiration Date: May 24, 2012
    COMMERCIAL SUPPORT
    This activity is being supported by an educational grant from Pfizer Inc.
    This continuing medical education activity is provided by The University of Texas Southwestern Medical Center in collaboration with RealCME and the Neuroscience Education Institute.